Acadia Healthcare Company, Inc. (ACHC)
USD 39.05
(-1.49%)
USD 39.05
(-1.49%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 189.11 Million USD | 13.76% |
| 2022 | 561.67 Million USD | 7.77% |
| 2021 | 459.47 Million USD | 13.09% |
| 2020 | 437.15 Million USD | -18.94% |
| 2019 | 402.01 Million USD | -0.52% |
| 2018 | 385.88 Million USD | -1.6% |
| 2017 | 580.89 Million USD | 0.11% |
| 2016 | 580.24 Million USD | 50.96% |
| 2015 | 384.36 Million USD | 87.1% |
| 2014 | 205.43 Million USD | 46.65% |
| 2013 | 140.08 Million USD | 78.02% |
| 2012 | 70.58 Million USD | 417.6% |
| 2011 | -24.77 Million USD | -379.27% |
| 2010 | 8.87 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 166.13 Million USD | -3.23% |
| 2024 Q1 | 165.25 Million USD | 3.01% |
| 2024 Q2 | 178.77 Million USD | 3.89% |
| 2023 Q3 | 172.16 Million USD | 3.02% |
| 2023 Q4 | 160.42 Million USD | -6.82% |
| 2023 Q2 | 167.12 Million USD | 21.8% |
| 2023 FY | - USD | 13.76% |
| 2023 Q1 | 137.21 Million USD | -0.3% |
| 2022 Q3 | 144.67 Million USD | -6.87% |
| 2022 Q1 | 124.02 Million USD | -13.59% |
| 2022 Q4 | 137.61 Million USD | -4.88% |
| 2022 FY | - USD | 7.77% |
| 2022 Q2 | 155.35 Million USD | 25.26% |
| 2021 Q2 | 132.22 Million USD | 17.53% |
| 2021 Q4 | 143.52 Million USD | 7.97% |
| 2021 Q3 | 132.93 Million USD | 0.54% |
| 2021 Q1 | 112.5 Million USD | -25.8% |
| 2021 FY | - USD | 13.09% |
| 2020 Q1 | 127.87 Million USD | -9.55% |
| 2020 FY | - USD | -18.94% |
| 2020 Q2 | 138.61 Million USD | 8.4% |
| 2020 Q3 | 153.93 Million USD | 11.05% |
| 2020 Q4 | 151.62 Million USD | -1.5% |
| 2019 FY | - USD | -0.52% |
| 2019 Q2 | 154.7 Million USD | 23.19% |
| 2019 Q3 | 136.82 Million USD | -11.56% |
| 2019 Q4 | 141.37 Million USD | 3.32% |
| 2019 Q1 | 125.58 Million USD | -4.27% |
| 2018 FY | - USD | -1.6% |
| 2018 Q4 | 131.17 Million USD | -8.71% |
| 2018 Q3 | 143.69 Million USD | -8.99% |
| 2018 Q2 | 157.88 Million USD | 13.74% |
| 2018 Q1 | 138.81 Million USD | -6.87% |
| 2017 Q4 | 149.05 Million USD | 0.66% |
| 2017 Q1 | 128.97 Million USD | -9.27% |
| 2017 FY | - USD | 0.11% |
| 2017 Q2 | 145.73 Million USD | 12.99% |
| 2017 Q3 | 148.08 Million USD | 1.61% |
| 2016 FY | - USD | 50.96% |
| 2016 Q3 | 147.58 Million USD | -7.33% |
| 2016 Q1 | 97.75 Million USD | -7.73% |
| 2016 Q2 | 159.26 Million USD | 62.92% |
| 2016 Q4 | 142.15 Million USD | -3.68% |
| 2015 FY | - USD | 87.1% |
| 2015 Q4 | 105.95 Million USD | 2.73% |
| 2015 Q3 | 103.14 Million USD | 2.68% |
| 2015 Q2 | 100.44 Million USD | 34.26% |
| 2015 Q1 | 74.81 Million USD | 18.12% |
| 2014 Q4 | 63.34 Million USD | 13.07% |
| 2014 Q2 | 42.3 Million USD | 12.77% |
| 2014 Q3 | 56.02 Million USD | 32.41% |
| 2014 Q1 | 37.51 Million USD | -0.46% |
| 2014 FY | - USD | 46.65% |
| 2013 Q4 | 37.69 Million USD | 1.46% |
| 2013 Q1 | 29.94 Million USD | 26.04% |
| 2013 Q2 | 35.3 Million USD | 17.91% |
| 2013 FY | - USD | 78.02% |
| 2013 Q3 | 37.15 Million USD | 5.23% |
| 2012 Q2 | 19.13 Million USD | 37.38% |
| 2012 Q3 | 19.82 Million USD | 3.57% |
| 2012 Q1 | 13.93 Million USD | 181.0% |
| 2012 Q4 | 23.75 Million USD | 19.85% |
| 2012 FY | - USD | 417.6% |
| 2011 Q4 | -17.19 Million USD | -331.5% |
| 2011 Q2 | -14.99 Million USD | -24090.32% |
| 2011 FY | - USD | -379.27% |
| 2011 Q1 | -62 Thousand USD | -104.24% |
| 2011 Q3 | 7.42 Million USD | 149.53% |
| 2010 Q4 | 1.46 Million USD | -35.27% |
| 2010 Q3 | 2.26 Million USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Addus HomeCare Corporation | 106.55 Million USD | -77.475% |
| AirSculpt Technologies, Inc. | 28.31 Million USD | -567.964% |
| Amedisys, Inc. | 216.91 Million USD | 12.816% |
| American Oncology Network, Inc. | -39.35 Million USD | 580.582% |
| Astrana Health, Inc. | 123.68 Million USD | -52.896% |
| Aveanna Healthcare Holdings Inc. | 44.34 Million USD | -326.432% |
| IMAC Holdings, Inc. | -5.94 Million USD | 3280.1% |
| biote Corp. | 9.23 Million USD | -1948.018% |
| Cryo-Cell International, Inc. | -10.41 Million USD | 1915.386% |
| Cross Country Healthcare, Inc. | 129.33 Million USD | -46.22% |
| COMPASS Pathways plc | -123.8 Million USD | 252.755% |
| DocGo Inc. | 32.72 Million USD | -477.885% |
| The Ensign Group, Inc. | 353.23 Million USD | 46.462% |
| Healthcare Services Group, Inc. | 75.21 Million USD | -151.441% |
| InnovAge Holding Corp. | 1.15 Million USD | -16287.695% |
| Assure Holdings Corp. | -19.82 Million USD | 1053.965% |
| The Joint Corp. | 9.14 Million USD | -1968.692% |
| LifeStance Health Group, Inc. | -104.92 Million USD | 280.236% |
| Mobile-health Network Solutions Class A Ordinary Shares | -15.55 Million USD | 1315.802% |
| ModivCare Inc. | -26.75 Million USD | 806.968% |
| NewGenIvf Group Limited | 384.3 Thousand USD | -49109.352% |
| Novo Integrated Sciences, Inc. | -5.84 Million USD | 3333.27% |
| Option Care Health, Inc. | 376.79 Million USD | 49.81% |
| P3 Health Partners Inc. | -81.07 Million USD | 333.27% |
| P3 Health Partners Inc. | -81.07 Million USD | 333.27% |
| The Pennant Group, Inc. | 30.36 Million USD | -522.721% |
| Surgery Partners, Inc. | 446.1 Million USD | 57.607% |
| Syra Health Corp. Class A Common Stock | -2.83 Million USD | 6768.604% |
| Talkspace, Inc. | -22.01 Million USD | 959.101% |
| Talkspace, Inc. | -22.01 Million USD | 959.101% |
| The Oncology Institute, Inc. | -70.45 Million USD | 368.422% |
| The Oncology Institute, Inc. | -70.45 Million USD | 368.422% |